Numbers in contact with drug and alcohol services between April 2018 and March 2019 remains flat at around 268,000.
The PDA-Boots tussle has ended but will there be a law change making it easier to end sweetheart union arrangements?
New vaccination data highlights that there’s work to be done to improve childhood vaccination rates, despite some positive signs.
The UK’s major pharmacy businesses appear to be going through a period of reckoning as cuts begin to really bite
A £26.6bn fund set aside for a no-deal Brexit will go towards boosting public spending if the UK leaves with a deal
Twelve months after its introduction, what impact has the defence against prosecution for a dispensing error had?
Pharmacy minister Steve Brine told delegates the Government was “crystal clear” about the importance of pharmacy
As of February 2019, 32 investigations have been initiated and 86 suspects arrested or interviewed under caution
How are pharmacy and pharmaceutical players ensuring patients have access to medicines post-Brexit?
Matt Hancock revealed in the course of the hearing that the Government has “of course” prioritised medicines over food
The ‘watch list’ of medicines that could be affected by Brexit includes essential drugs such as radiotherapy products
Pharmacies not yet compliant with the Falsified Medicines Directive still have time – but the clock is ticking...
Initially slated for December, it now appears likely that the App will not become fully operational until early 2019
The NHS across the UK is expected to save around £930m on its medicine bill under a new scheme
NHS England has set out plans to curb the prescribing of a further group of ‘low priority’ items such as silk garments
The Department of Health (Northern Ireland) has announced additional community pharmacy funding of up to £11.1m
Industry voices have welcomed the Brexit draft withdrawal plan but severe concerns remain
The NPA described the ruling as a positive outcome for pharmacists, patients and the NHS
Certain medical products derived from cannabis are now available on prescription in the UK. Richard Hough examines a decision that could have wide-ranging implications for patients…
Pharmaceutical companies have good rates of reporting, the Committee says, but the picture is much more mixed for universities and PHE
